{
  "@context": {
    "biotools": "https://bio.tools/ontology/",
    "bsc": "http://bioschemas.org/",
    "bsct": "http://bioschemas.org/types/",
    "dct": "http://purl.org/dc/terms/",
    "edam": "http://edamontology.org/",
    "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "rdfs": "http://www.w3.org/2000/01/rdf-schema#",
    "sc": "http://schema.org/",
    "xsd": "http://www.w3.org/2001/XMLSchema#"
  },
  "@graph": [
    {
      "@id": "https://bio.tools/h-racs",
      "@type": "sc:SoftwareApplication",
      "dct:conformsTo": "https://bioschemas.org/profiles/ComputationalTool/0.6-DRAFT",
      "sc:additionalType": "Web application",
      "sc:applicationSubCategory": [
        {
          "@id": "edam:topic_0154"
        },
        {
          "@id": "edam:topic_0091"
        },
        {
          "@id": "edam:topic_3375"
        },
        {
          "@id": "edam:topic_2640"
        },
        {
          "@id": "edam:topic_0209"
        }
      ],
      "sc:citation": [
        {
          "@id": "https://doi.org/10.18632/AGING.103925"
        },
        "pubmed:33173014",
        "pmcid:PMC7695372"
      ],
      "sc:description": "A handy tool to rank anti-cancer synergistic drugs.\n\nH-RACS is designed to predict synergistic drug combinations based on drug features and basal expression profiling of cancer context. The advantages of H-RACS lie in 1) excellent performance with minimum data input compared to peers; 2) abundant cancer context built-in covering 928 cell lines of 24 cancers; 3) unique and outstanding extendibility to new drug combinations and new cell lines.",
      "sc:featureList": {
        "@id": "edam:operation_3435"
      },
      "sc:name": "H-RACS",
      "sc:url": "http://www.badd-cao.net/h-racs"
    },
    {
      "@id": "https://doi.org/10.18632/AGING.103925",
      "@type": "sc:CreativeWork"
    }
  ]
}